Sepsis News and Research

Latest Sepsis News and Research

Study could lead to a potential new way of treating sepsis

Australian emergency doctors are at the forefront of a large clinical study to assess how clinicians are treating sepsis.

11 Dec 2018

Using nanocarrier-delivered microRNA to target sepsis

One in three patients who die in the U.S. dies of sepsis, according to the Centers for Disease Control and Prevention. It is one of the leading causes of death in intensive care units and, with an estimated price tag of $20 billion in 2011, the most expensive condition that hospitals treat.

3 Dec 2018

Transfusions with older blood may increase risk of death, adverse events

After a serious injury, the leading cause of death is loss of blood. Major trauma victims who receive transfusions of packed blood 22 days old or older may face increased risk of death within 24 hours, according to a new study in Annals of Emergency Medicine.

28 Nov 2018

Researchers identify sepsis symptoms that contribute to patient mortality

Using patient records from 210,289 hospital visits between 2013 and 2016, Drexel University researchers have identified the specific symptoms that put patients at the greatest risk of dying from sepsis - and they're not what many clinicians might think.

26 Nov 2018

Study highlights need for better screening tools to detect maternal sepsis

A woman lies in her hospital bed. Her heart rate is elevated, she has a slight fever and an elevated white blood cell count.

21 Nov 2018

Scientists discover new inhibitor that decreases lung inflammation

Scientists from the University of Sheffield have discovered a new inhibitor which decreases lung inflammation and could hold the key to treating Acute Respiratory Distress Syndrome - a life-threatening disease which affects thousands of people in the UK.

18 Nov 2018

Specific bacterial toxins reduce number of cells suppressing immune response

Staphylococcus aureus bacteria can cause numerous diseases, such as skin infections, pneumonia and blood poisoning.

16 Nov 2018

Researchers develop new drug molecule that inhibits inflammation

A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.

15 Nov 2018

Nicoya designate the Institute for Stem Cell Biology and Regenerative Medicine as the OpenSPR Centre of Excellence

Currently in India, there are over 200,000 researchers working on numerous applications to better understand diseases and advance drug discovery. To support their discoveries, we are thrilled to announce the opening of the OpenSPR Centre of Excellence in Bangalore, India!

From Nicoya Lifesciences 15 Nov 2018

Severe maternal morbidities highly linked to pregnant woman's risk of death

The number of severe maternal morbidities (SMM) a pregnant woman has is highly linked to her risk of maternal death, according to a new study by researchers at ICES and St. Michael's Hospital.

9 Nov 2018

Researchers develop technique to disrupt communication between microorganisms

The World Health Organization considers Pseudomonas aeruginosa a germ requiring urgent action to prevent and control its spread. The bacteria can cause a variety of diseases from chronic lung infections to sepsis.

8 Nov 2018

Antibiotic resistance likely to kill 2.4 million across Europe, Australia and North America by 2050

Antibiotic resistance is one of the hottest concerns worldwide today and is likely to take back the human civilization to the pre-antibiotic era at this rate. A new report titled “Stemming the Superbug Tide”, has speculated that antibiotic resistant bugs are soon likely to kill over 90,000 Britons over the next three decades if it is not curbed now.

7 Nov 2018

Predictive model could improve sepsis care

Researchers from MIT and Massachusetts General Hospital have developed a predictive model that could guide clinicians in deciding when to give potentially life-saving drugs to patients being treated for sepsis in the emergency room.

7 Nov 2018

Elderly LS-SCLC patients show similar results to younger counterparts for concurrent chemo-radiotherapy

Elderly patients with limited-stage small cell lung cancer showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy. Concurrent chemo-radiotherapy should be a treatment option for fit patients aged 70 years or older.

2 Nov 2018

Novel technique potentially more effective in fighting against ovarian cancer

Instead of destroying a tumors' blood supply, a first-ever University of Guelph study has proven that opening up the vessels is potentially more effective when it comes to fighting ovarian cancer.

30 Oct 2018

Stroke 'mimics' and 'chameleons' can complicate accurate diagnoses

Stroke specialists often see conditions known as stroke "mimics" and "chameleons" that can complicate accurate diagnoses, Loyola Medicine neurologists report in the November 2018 issue of Neuroimaging Clinics of North America.

26 Oct 2018

Researchers use neutrons to explore complex outer surfaces of E.coli

Researchers have been using neutrons to explore the complex outer surfaces of the bacterium Escherichia coli, and they have revealed in the process, with great precision and detail, how such bacteria interact with their surroundings.

25 Oct 2018

New diagnostic platform simultaneously screens for all known pathogenic bacteria

Scientists at the Center for Infection and Immunity in the Columbia University Mailman School of Public Health have developed the first diagnostic platform that can simultaneously screen for all known human pathogenic bacteria as well as markers for virulence and antibiotic resistance.

23 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018